Startup profile · funding coverage
Hone Health funding, valuation and investors
US physician-led diagnostics and longevity telehealth company; disclosed a $228M financing package comprising $28M equity and $200M customer-value growth financing.
Verified company research · funding, investors and latest developments
Keep track of Hone Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A equity financing / extension
$28M · November 18, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$28M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · New York, New York, United States
Investors in latest funding
Lead: MarcyPen Capital Partners
Other: Pentland Ventures , Kinship Ventures , Hanwha , Gannet Capital
Overview
Hone Health, led by co-founder and CEO Saad Alam, offers US telehealth-led longitudinal diagnostics, physician consultations and eligible prescription programs. On November 18, 2026 the company announced $28M Series A equity financing led by MarcyPen Capital Partners plus $200M in separate growth financing from General Catalyst's Customer Value Fund. Total equity raised is $65M per issuer.
Pricing depends on tier and medications are extra; physician suitability and state licensing govern treatment eligibility. The company is unrelated to Hone (hone.com), the enterprise-agent startup.
Why Hone Health is interesting
Issuer financial breakdown shows only $28M of the $228M package is Series A equity, with $200M from General Catalyst's Customer Value Fund for growth; this is neither $228M new equity nor the unrelated Hone enterprise-AI startup already indexed by VCT.
Product & use cases
Illustrative US buyer journey: review geographic and clinical eligibility, choose Basic/Plus/Premium tier, complete history and labs, review biomarker results, book optional/included licensed-physician consultation, and receive a clinician-directed treatment plan and follow-up tests where appropriate. Public help pages list Basic $25/month, Plus $135/month, Premium $155/month; consultations may be separate on Basic and prescribed medications are charged extra. No claimed wellness improvement is a substitute for clinical efficacy evidence.
- Longitudinal biomarker testing and physician-guided telehealth for eligible adults
- Optional clinician-review and prescription pathways where medically appropriate and state-authorized
- Periodic monitoring of symptoms and labs with direct-to-consumer membership pricing
Key facts
- Nov 18 company release: $28M Series A equity plus $200M General Catalyst CVF growth financing.
- Total disclosed equity funding is $65M; $228M package is not all equity.
- Basic $25, Plus $135, Premium $155 per month as shown in vendor help pages; medication extra.
- Hone Health is a different legal/product identity from Hone enterprise AI (hone.com).
Funding history (newest first)
Series A equity financing / extension
2026-11-18 $28M- MarcyPen Capital Partners (lead)
- Pentland Ventures (participant)
- Kinship Ventures (participant)
- Hanwha (participant)
- Gannet Capital (participant)
Source: Read source · prnewswire.com
General Catalyst Customer Value Fund growth financing (non-equity, structure not fully disclosed)
2026-11-18 $200M- General Catalyst Customer Value Fund (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: Bundling diagnostics and clinician consultations in ongoing membership for US consumers, subject to provider availability and medical eligibility.
Provider claims, customer selection and biomarkers do not prove longer life or clinical benefit. A buyer must compare included lab panels, physician access, extra prescriptions and the evidence for each intervention; the financing package's growth capital is not Series A equity.
-
Function Health adjacent
Subscription biomarker testing and insights; clinician treatment availability differs.
-
InsideTracker adjacent
Biomarker-driven wellness analysis and subscriptions.
-
Ro direct
Direct-to-consumer telehealth and prescriptions; disease areas and fees vary.
-
Marek Health direct
Health optimization labs and clinician services; program structure differs.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Hone Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.